Mayne Pharma Group Limited

DUSE:HG60 Stock Report

Market Cap: €199.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Mayne Pharma Group Management

Management criteria checks 1/4

Key information

Shawn O’Brien

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2yrs
Board average tenure1.1yrs

Recent management updates

No updates

Recent updates

No updates

CEO

Shawn O’Brien

less than a year

Tenure

Mr. Shawn Patrick O'Brien, B.Sc has been CEO, MD & Director at Mayne Pharma Group Limited since October 1, 2022. He serves as the Chief Commercial Advisor at Melanovus Oncology, Inc. Mr. O'Brien is a found...

Leadership Team

NamePositionTenureCompensationOwnership
Shawn O’Brien
CEO, MD & Directorless than a yearno datano data
Aaron Gray
Chief Financial Officerless than a yearno datano data
Kimberly Parker
Executive VP & General Counselless than a yearno datano data
Brant Schofield
Executive Vice President of Corporate Development2yrsAU$1.29mno data
Andrew Herdman
Vice President of Group Human Resources4.3yrsno datano data
Stefan Cross
President of International Operations6yrsAU$1.01mno data
Daniel Moore
Executive Vice President of Specialty Products & Patient Solutions3.3yrsno datano data
Gerard Nahum
Chief Medical Officer2yrsno datano data
Hemanshu Pandya
Senior VP & Head of Generic Product Division1.3yrsno datano data
Brenton Walter
Financial Controller18.5yrsno datano data
Laura Loftus
Associate General Counsel & Company Secretary2.8yrsno datano data

2.0yrs

Average Tenure

Experienced Management: HG60's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shawn O’Brien
CEO, MD & Directorless than a yearno datano data
Frank Condella
Independent Non-Executive Chairman4.7yrsAU$260.13k0.043%
€ 86.5k
Carolyn Myers
Non-Executive Director1.3yrsAU$139.17kno data
Bruce G. Robinson
Independent Non-Executive Director8.4yrsAU$148.50k0.036%
€ 72.7k
Patrick Blake
Independent Non-Executive Director4.6yrsAU$200.80k0.015%
€ 29.8k
Ann Custin
Independent Non-Executive Directorless than a yearAU$54.58kno data
Kathryn MacFarlane
Independent Non-Executive Directorless than a yearAU$81.71kno data
David Petrie
Independent Non-Executive Directorless than a yearno datano data

1.1yrs

Average Tenure

63yo

Average Age

Experienced Board: HG60's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/01/25 23:28
End of Day Share Price 2023/01/19 00:00
Earnings2022/06/30
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter